SecBot SecBot
SECBOTREPLAY Home › Report › OTLK

OTLK · Outlook Therapeutics announced FDA acceptance of its resubmitted BLA…

Outlook Therapeutics, Inc. · PRESS-RELEASE filed Jun 16, 2026 at 08:02 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Jun 16, 2026 at 08:02 ET

Outlook Therapeutics announced FDA acceptance of its resubmitted BLA for ONS-5010/LYTENAVA (bevacizumab-vikg) for wet AMD as a Class 1 review with a PDUFA target date of July 29, 2026. The company has initiated pre-launch activities, and approval would make it the first FDA-approved ophthalmic formulation of bevacizumab with standardized manufacturing and labeling. This is a major regulatory milestone for a $162M market-cap biotech with a single primary asset.

  • FDA accepted resubmitted BLA for ONS-5010/LYTENAVA as Class 1 review
  • PDUFA target action date set for July 29, 2026
  • ONS-5010/LYTENAVA already has EU and UK marketing authorization for wet AMD
  • Company has initiated pre-launch activities in anticipation of potential approval

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access